^
    3d
    DUET study: DUET-study: A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AFTER CURATIVE THERAPY. (2024-518985-29-02)
    P1/2, N=6, Completed, Amsterdam UMC Stichting | Active, not recruiting --> Completed
    Trial completion
    |
    FOLH1 expression
    |
    Xofigo (radium Ra-223 dichloride)
    4d
    MTI201-IA: Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, Modulation Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2026 --> Mar 2027
    Enrollment closed • Trial primary completion date • First-in-human
    4d
    BANTAM-01: A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer (clinicaltrials.gov)
    P1, N=148, Recruiting, Bayer | Trial completion date: Dec 2033 --> Aug 2031 | Trial primary completion date: Jul 2030 --> Jul 2029
    Trial completion date • Trial primary completion date • First-in-human
    |
    GPC3 (Glypican 3)
    8d
    Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Weill Medical College of Cornell University | Suspended --> Active, not recruiting | Phase classification: P1/2 --> P1 | N=48 --> 20 | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Dec 2026 --> Dec 2027
    Enrollment closed • Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    CELLSEARCH®
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    8d
    PAnTHA: First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P1, N=198, Recruiting, Bayer | N=73 --> 198 | Trial completion date: May 2031 --> May 2032 | Trial primary completion date: Jun 2027 --> Nov 2028
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    FOLH1 positive
    9d
    ACTION-1: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (clinicaltrials.gov)
    P3, N=338, Recruiting, RayzeBio, Inc. | Trial completion date: Jul 2028 --> Dec 2030
    Trial completion date
    |
    SSTR (Somatostatin Receptor)
    |
    sunitinib • everolimus • Actinium-225 DOTATATE (RYZ101)
    21d
    TRACY-1: Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. (clinicaltrials.gov)
    P1/2, N=16, Active, not recruiting, RayzeBio, Inc. | Recruiting --> Active, not recruiting | N=124 --> 16
    Enrollment closed • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • SSTR (Somatostatin Receptor)
    |
    HER-2 negative
    |
    Actinium-225 DOTATATE (RYZ101)
    29d
    Radium-223 in Biochemically Recurrent Prostate Cancer (clinicaltrials.gov)
    P2, N=19, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2027 --> Jul 2026 | Trial primary completion date: Nov 2026 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    Xofigo (radium Ra-223 dichloride)
    1m
    Initial Clinical Experience with [177Lu]Lu-RTX-2358 Radiopharmaceutical Therapy Targeting Fibroblast Activation Protein: Biodistribution, Pharmacokinetics, and Dosimetry. (PubMed, J Nucl Med)
    [177Lu]Lu-RTX-2358 demonstrated a manageable safety profile in a series of patients who were heavily pretreated for their disease. Given a promising therapeutic index as a result of prolonged retention in tumors and clearance from normal organs, further clinical evaluation is warranted.
    PK/PD data • Journal
    |
    FAP (Fibroblast activation protein, alpha)
    1m
    IRST185.04: Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC) (2024-511660-89-00)
    P1/2, N=70, Active, not recruiting, Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    docetaxel • prednisone • Xofigo (radium Ra-223 dichloride)
    2ms
    Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, National Cancer Institute (NCI)
    New P1 trial • Tumor mutational burden • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    IDH wild-type • IDH1 R132
    |
    Libtayo (cemiplimab-rwlc) • Actimab-A (lintuzumab-Ac225) • Zamyl (lintuzumab)
    2ms
    Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study). (clinicaltrials.gov)
    P1/2, N=100, Recruiting, AdvanCell Pty Limited | Trial completion date: Dec 2029 --> Jun 2029 | Trial primary completion date: Dec 2027 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    FOLH1 positive